What is Clarus Therapeutics Holdings Earnings Power Value (EPV)?
As of Jun22, Clarus Therapeutics Holdings's earnings power value is $-0.48. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Clarus Therapeutics Holdings Earnings Power Value (EPV) Historical Data
The historical data trend for Clarus Therapeutics Holdings's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clarus Therapeutics Holdings Earnings Power Value (EPV) Chart
|
Clarus Therapeutics Holdings Annual Data
|
|
Trend |
Dec20 |
Dec21 |
| Earnings Power Value (EPV) |
|
- |
- |
|
Clarus Therapeutics Holdings Quarterly Data
|
|
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
- |
- |
- |
- |
- |
Competitive Comparison of Clarus Therapeutics Holdings's Earnings Power Value (EPV)
For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clarus Therapeutics Holdings's Earnings Power Value (EPV) Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Clarus Therapeutics Holdings's Earnings Power Value (EPV) falls into.
Clarus Therapeutics Holdings Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description
Traded in Other Exchanges
N/A
Address
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Executives
| Thomas Mcnerney & Partners Lp |
10 percent owner |
45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402 |
| Kimberly M Murphy |
director |
101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602 |
| Elizabeth Cermak |
director |
1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517 |
| Prygocki Mark A Sr |
director |
C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258 |
| John Kenneth Amory |
director |
C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662 |
| Robert E. Dudley |
director, officer: Chief Executive Officer |
555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062 |
| Joseph Hernandez |
director |
C/O MICROLIN BIO, INC., NEW YORK NY 10022 |
| Richard D Peterson |
officer: Chief Financial Officer |
1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309 |
| Frank Jaeger |
officer: Chief Commercial Officer |
CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662 |
| Steven A. Bourne |
officer: Chief Administrative Officer |
555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062 |
| Ffi Fund Ltd |
10 percent owner |
DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208 |
| Thomas, Mcnerney & Partners Ii L.p. |
10 percent owner |
45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402 |
| Thomas, Mcnerney & Partners Ii, Llc |
10 percent owner |
45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
| Tmp Nominee Ii, Llc |
10 percent owner |
45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
| Tmp Associates Ii Lp |
10 percent owner |
45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRXTQ has been successfully added to your